Relay Therapeutics (RLAY) Total Liabilities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Total Liabilities data on file, last reported at $57.4 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $57.4 million, down 26.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.4 million (down 26.64% YoY), and the FY2025 annual result was $54.3 million, down 41.96% from the prior year.
• Total Liabilities advanced to $57.4 million in Q1 2026 per RLAY's latest filing, from $54.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $168.9 million in Q3 2022 and troughed at $54.3 million in Q4 2025.
• A 5-year average of $102.9 million and a median of $93.5 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 179.84% in 2022, then slumped 41.96% in 2025.
• A 5-year view of Total Liabilities shows it stood at $149.6 million in 2022, then sank by 38.5% to $92.0 million in 2023, then advanced by 1.66% to $93.5 million in 2024, then tumbled by 41.96% to $54.3 million in 2025, then advanced by 5.82% to $57.4 million in 2026.
• Business Quant data shows RLAY's Total Liabilities at $57.4 million in Q1 2026, $54.3 million in Q4 2025, and $62.3 million in Q3 2025.